A Long-term Response to Nivolumab in a Case of PD-L1-negative Lung Adenocarcinoma with an EGFR Mutation and Surrounding PD-L1-positive Tumor-associated Macrophages

Lignende værker

• Beneficial Effect of Osimertinib Readministration in Non-small-cell Lung Cancer Harboring an Epidermal Growth Factor Receptor (EGFR) Mutation with a History of Acquired Resistance to Osimertinib
  af: Makimoto, Go, et al.
  Udgivet: (2019)
• Successful Re-administration of Osimertinib in Osimertinib-induced Interstitial Lung Disease with an Organizing Pneumonia Pattern: A Case Report and Literature Review
  af: Itano, Junko, et al.
  Udgivet: (2019)
• Rapid and Long-term Response of Pulmonary Pleomorphic Carcinoma to Nivolumab
  af: Senoo, Satoru, et al.
  Udgivet: (2018)
• Triple therapy with osimertinib, bevacizumab and cetuximab in EGFR-mutant lung cancer with HIF-1α/TGF-α expression
  af: Nishii, Kazuya, et al.
  Udgivet: (2021)
• MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib
  af: Ninomiya, Kiichiro, et al.
  Udgivet: (2018)